Retatrutide, a novel dual stimulator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising data in initial patient trials . Ongoing research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/